Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
A $100 million buyback authorization from United States Antimony landed just days after a badly missed quarter and a guidance cut that nearly halved the full-year outlook, raising a pointed question about whether management is signaling confidence or buying time.
Nelson Peltz is circling Wendy's with a take-private consortium even as the burger chain logs its sixth straight quarter of falling sales and shutters hundreds of restaurants. Whether deal fever or a genuine turnaround is driving this stock surge is the question every investor needs to answer before acting.
Management is deploying record AI cash flow after the stock nearly halved from June's peak.
Enterprise Products Partners has proven to be a very bankable income investment over the long term.
Agency mortgage REITs promise fat monthly checks backed by government-guaranteed bonds, but leverage cuts both ways and dividend histories here are brutal. Three names keep pulling income investors back despite the scars.
OpenAI, Anthropic, Meta, and AWS are all competing for the same scarce silicon, and one chipmaker sits at the center of every deal. Whether that position justifies the current price depends on a set of risk factors most investors have not priced in.
Tesla's stock is on track for its worst performance since 2022, but back then, the markets as a whole were struggling.
Most stocks rose Wednesday, but a few big tech names told a different story. Here's what split the market again.
The treatment combines an mRNA shot with Merck's Keytruda.
The smartest move is to simply do nothing.
During the second quarter, Berkshire became a net buyer of stocks for the first time in over three years.
As usual, Warren Buffett said it best.
Lee Ainslie just torched Maverick Capital's playbook, dumping chip giants to pour hundreds of millions into five names that look nothing like his fund's typical bets, and one of them involves derivatives on a Brazilian fintech.
Lilly, Novo, and Merck have each priced in a radically different version of the next two years, and one of them looks like a setup where the market has it badly wrong.
Greg Abel just committed $6.8 billion to homebuilders while mortgage rates hover near 7% and builder sentiment sits at multi-year lows. Whether that looks like bold contrarian conviction or a costly miscalculation depends on what happens next.
NetEase has quietly staged a double-digit comeback from its April lows, and its next earnings report could be the moment the market finally catches up to what the numbers have been saying all along.
There were several bright spots in the earnings report. Investors are looking elsewhere.
When the 30-year Treasury topped 5%, two dividend stocks moved in completely opposite directions on the same day, and the reason has nothing to do with their yields.
Small-cap investors have been disappointed for years. Here's why that trend might finally be ready to reverse.
JEPI built its reputation as the go-to defensive income ETF, but a smaller Fidelity rival running a similar playbook has quietly left it in the dust this year while charging even less to hold it.
With the 30-year Treasury sitting above 5%, a fat dividend yield stops being a reward and starts being a warning sign. Five popular income stocks are failing a coverage checklist that separates genuine payouts from traps waiting to spring.
Another big payout from the warehouse club operator should be coming soon.
Nuclear energy is making a comeback, and two American companies are poised to flourish as the industry landscape evolves.
Oracle just reported a backlog so massive it rivals Microsoft's entire commercial pipeline, yet the stock sits 40% below where it traded a year ago. Something has to give, and figuring out which way raises billions of dollars worth of questions.
Yields dropped on the news that the government just became its own best customer
Bank of America sees Nvidia shares trading at a steep discount to where they should be, but the bold price target rests on assumptions that could unravel fast given the debt piling up across the AI industry.
Jim Cramer says the 2026 software selloff has crossed a line, and the market is no longer pricing in missed earnings but betting on total extinction. Whether that fear has any grounding in reality is a very different question.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
